A Study of IBI362 9 mg in Chinese Adults With Obesity

Summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical study evaluating the efficacy and safety of IBI362 9 mg in obese subjects. Subjects will be randomly assigned to IBI362 9 mg and placebo groups. All study treatment will be administered once-weekly and subcutaneously. The entire trial cycle includes a 2-week screening period, a 60-week double-blind treatment period, and a 12-week drug withdrawal follow-up period after the end of treatment.

Timeline

Start

2023-12-27

Primary completion

2025-06-27

Completion

2025-09-19

Outcome

Met primary endpoint

paper mean percentage change in body weight from baseline was -16.65% (95% CI, -18.19% to -15.12%) in the mazdutide group compared with -1.50% (95% CI, PMID 42251595 ↗

paper between-group difference, -15.15% [95% CI, -17.22% to -13.09%]; P < .001). PMID 42251595 ↗

paper 84.3% of participants in the mazdutide group had a body weight reduction of 5% or greater compared with 33.1% in the placebo group PMID 42251595 ↗

release “in Chinese adults with obesity (GLORY-2) met the primary endpoints and all key secondary endpoints.” innoventbio.com ↗

release “In November 2025, the Phase 3 GLORY-2 study of mazdutide 9 mg met its primary endpoint and all key secondary endpoints” innoventbio.com ↗

Publications

• Gao L, Jiang H, Cai H, Tian J, Shi B, Qiu W, Huang C, Han J, Zhang S, Pang S, Bi Y, Chen L, Gu X, Han J, Ma Q, Deng H, Wang Y, Li L, Han-Zhang H, Qian L, Ji L; GLORY-2 Trial Investigators. Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial. JAMA. 2026 Jun 7:e268142. doi: 10.1001/jama.2026.8142. Online ahead of print.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mazdutide	Protein / enzyme biologic	9 mg	Subcutaneous

Indications